Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
Delayed Nasdaq  -  04:00 2022-10-06 pm EDT
15.60 USD   -2.38%
10/04Exelixis, Bristol-Myers Squibb Expand Clinical Trial Collaboration in Solid Tumors Study
MT
10/04Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
BU
09/15Transcript : Exelixis, Inc. Presents at BofA Securities Global Healthcare Conference 2022, Sep-15-2022 01:10 PM
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/30/2022 10/03/2022 10/04/2022 10/05/2022 10/06/2022 Date
15.68(c) 16.35(c) 16.41(c) 15.98(c) 15.6 Last
2 950 425 3 055 156 3 224 808 2 857 074 3 997 801 Volume
-1.01% +4.27% +0.37% -2.62% -2.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 612 M - -
Net income 2022 295 M - -
Net cash position 2022 1 127 M - -
P/E ratio 2022 17,5x
Yield 2022 -
Sales 2023 1 848 M - -
Net income 2023 339 M - -
Net cash position 2023 1 317 M - -
P/E ratio 2023 14,8x
Yield 2023 -
Capitalization 5 021 M 5 021 M -
EV / Sales 2022 2,42x
EV / Sales 2023 2,00x
Nbr of Employees 954
Free-Float 97,8%
More Financials
Company
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with... 
More about the company
Ratings of Exelixis, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about EXELIXIS, INC.
10/04Exelixis, Bristol-Myers Squibb Expand Clinical Trial Collaboration in Solid Tumors Stud..
MT
10/04Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers S..
BU
09/15Transcript : Exelixis, Inc. Presents at BofA Securities Global Healthcare Con..
CI
09/13Transcript : Exelixis, Inc. Presents at Morgan Stanley 20th Annual Global Hea..
CI
09/12Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluatin..
AQ
09/10Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluatin..
BU
09/10Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Eva..
CI
09/07Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients w..
BU
09/07Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Pati..
CI
09/06Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
BU
09/02Exelixis Seeks to Block Generic Version of Kidney Cancer Drug
MT
09/02Exelixis, Inc. : Other Events (form 8-K)
AQ
08/25Bioinvent International Ab : Interim report January-June 2022
AQ
08/09Exelixis : Q2 2022 Earnings Slides With Appendix
PU
08/09Transcript : Exelixis, Inc., Q2 2022 Earnings Call, Aug 09, 2022
CI
More news
News in other languages on EXELIXIS, INC.
10/04Exelixis et Bristol-Myers Squibb étendent leur collaboration aux essais cliniques dans ..
09/10Exelixis, Inc. Annonce à l'ESMO 2022 des résultats de l'escalade de dose de l'essai de ..
09/07Exelixis, Inc. Annonce des résultats détaillés de l'essai pivot de phase 3 COSMIC-313 c..
08/09Exelixis annonce un bénéfice ajusté plus faible au deuxième trimestre et maintient ses ..
08/09Earnings Flash (EXEL) EXELIXIS affiche un chiffre d'affaires de 419,4 millions de dolla..
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
ETFs positioned on EXELIXIS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Genomics Immunology and Healthcare ...4.26%1.62%World
First Trust NYSE Arca Biotechnology Index F...4.16%3.08%United_States
First Trust NYSE Arca Biotechnology - Acc - USD3.37%2.38%-United_States
Invesco Dynamic Biotechnology & Genome ETF - USD3.06%2.28%United_States
VanEck Global Healthcare Leaders ETF - AUD2.11%4.23%-NC
More ETFs positioned on EXELIXIS, INC.
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 15,60 $
Average target price 26,85 $
Spread / Average Target 72,1%
EPS Revisions
Managers and Directors
Michael M. Morrissey President-Research & Development
Christopher J. Senner Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Director
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Vicki L. Goodman Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
EXELIXIS, INC.-12.58%5 143
REGENERON PHARMACEUTICALS, INC.18.08%79 719
VERTEX PHARMACEUTICALS37.53%77 456
BIONTECH SE-46.78%33 340
WUXI APPTEC CO., LTD.-39.54%29 208
GENMAB A/S1.14%22 982